Health Canada says it’s reviewing nine submissions for generic versions of popular weight loss medications that pharmaceutical experts say could bring down the price. The submissions in Canada are for generic forms of semaglutide, the active ingredient in Novo Nordisk's injectable prescription drugs Ozempic and Wegovy, which have been approved by Health Canada for diabetes and weight loss respectively. CBC News also asked Health Canada if it has received an application for a pill form of Wegovy